Skip to main content
Premium Trial:

Request an Annual Quote

Gene Data, Novartis

Premium

Gene Data of Basel, Switzerland, last week released two new modules for its analysis suite of products.

The firm, a 1997 spinout from Novartis, introduced Screener Condenser and Screener Analyst for its GeneData Screener system for the analysis of high-throughput screening data.

The Condenser product performs data standardization as well as data annotation. It is designed to integrate results from primary and secondary screening into bioactivity profiles.

The Analyst product is used for cross-assay compound profiling based on HTS data. It is intended for large-scale assay comparisions, biological activity profiling of compounds or compound libraries across large numbers of assays, separation of mechanisms of actions, and identification of chemical structural elements conferring a desired biological activity. The products, together, are intended to provide a data analysis workflow. They were developed in collaboration with the pharmaceutical company Altana Pharma.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.